OPEN Clinical cardiology | 18 Apr 2018
J Núñez, P Palau, E Domínguez, A Mollar, E Núñez, JM Ramón, G Miñana, E Santas, L Fácila, JL Górriz, J Sanchis and A Bayés-Genís
Sodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients.
* Data courtesy of Altmetric.com